Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.79 USD
Change Today -0.03 / -0.52%
Volume 13.7K
EARS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 1:45 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

auris medical ag (EARS) Snapshot

Open
$5.85
Previous Close
$5.82
Day High
$5.85
Day Low
$5.30
52 Week High
09/12/14 - $7.58
52 Week Low
12/23/14 - $3.30
Market Cap
167.6M
Average Volume 10 Days
15.4K
EPS TTM
$-0.84
Shares Outstanding
29.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AURIS MEDICAL AG (EARS)

Related News

No related news articles were found.

auris medical ag (EARS) Related Businessweek News

No Related Businessweek News Found

auris medical ag (EARS) Details

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical development for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss, as well as for Meniere diseases; and other development programs comprising AM-102 and AM-123 that are in preclinical studies. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

16 Employees
Last Reported Date: 04/22/15
Founded in 1998

auris medical ag (EARS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

auris medical ag (EARS) Key Developments

Auris Medical Holding AG Provides Update on Clinical Development Plan for AM-111

Auris Medical Holding AG provided an update on the clinical development of its AM-111 product candidate. AM-111 is being developed for the treatment of acute sensorineural hearing loss (ASNHL), an indication for which Auris Medical received Orphan Drug designation. Auris Medical is currently preparing two pivotal clinical trials with AM-111 in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL), which the company estimates to be the most frequent type of ASNHL. The company expects to start enrollment in the HEALOS trial in the third quarter of 2015 and in the ASSENT trial in the first quarter of 2016. In addition, Auris Medical is preparing a Phase 2 trial with AM-111 in the treatment of surgery-induced hearing loss called REACH. The company expects to start enrollment in REACH in the third quarter of 2016. As previously announced, the company plans to conduct HEALOS in Europe and Asia with approximately 255 patients. A single dose of either 0.4 mg/mL or 0.8 mg/mL of AM-111 will be compared to placebo in patients suffering from acute severe to profound hearing loss within 72 hours from ISSNHL onset. The FDA held a pre-IND meeting with the company in September 2014 and provided feedback and guidance on HEALOS. In response to this feedback and further Protocol Assistance from the EMA, the design of HEALOS was finalized. In addition, the company plans to conduct ASSENT in the U.S. in order to test AM-111 in a second ISSNHL trial with a similar number of patients as for HEALOS. The principal enrollment criteria will be identical to HEALOS, and patients will also be randomized to receive a single dose of either AM-111 0.4 mg/mL, AM-111 0.8 mg/mL or placebo by intratympanic injection. Unlike HEALOS, patients in ASSENT may receive a course of oral corticosteroid as background therapy. The company plans to discuss certain aspects of the study protocol with the FDA.

Auris Medical Holding AG Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:00 AM

Auris Medical Holding AG Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Auris Medical Holding AG Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Auris Medical Holding AG reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported operating loss of CHF 5,605,000 against CHF 3,278,000 a year ago. Loss before tax was CHF 3,973,000 against CHF 3,193,000 a year ago. Net loss attributable to owners of the company was CHF 3,973,000 against CHF 3,499,000 a year ago. Loss per share, basic and diluted was CHF 0.17 against CHF 0.24 a year ago. For the year, the company reported operating loss of CHF 22,194,000 against CHF 14,616,000 a year ago. Loss before tax was CHF 18,185,000 against CHF 14,699,000 a year ago. Net loss attributable to owners of the company was CHF 18,185,000 against CHF 15,004,000 a year ago. Loss per share, basic and diluted was CHF 0.66 against CHF 1.01 a year ago. The company expects the operating expenses for the 2015 financial year to be in the range of CHF 25.0 to CHF 30.0 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EARS:US $5.85 USD +0.03

EARS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EARS.
View Industry Companies
 

Industry Analysis

EARS

Industry Average

Valuation EARS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AURIS MEDICAL AG, please visit www.aurismedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.